Facing a challenging diagnosis like neuroblastoma can be incredibly daunting, especially for young children and their families. But what if there was a way to improve treatment outcomes for those whose cancer doesn't respond to initial therapies or returns after remission?
Recent findings from the BEACON phase 2 clinical trial, spearheaded by an international team of researchers and coordinated by the University of Birmingham's Cancer Research UK Clinical Trials Unit, offer a glimmer of hope. The study focused on children with high-risk neuroblastoma, a rare form of cancer. The results, published in the Journal of Clinical Oncology, indicate that incorporating dinutuximab beta (dB), a monoclonal antibody treatment, alongside standard chemotherapy can lead to significant tumor shrinkage.
So, what does this mean in practical terms?
The study revealed that children receiving dB in addition to standard chemotherapy experienced a significantly improved best objective response rate (ORR). This crucial metric measures the percentage of patients whose cancer either completely disappears or shows a substantial reduction. While the standard treatment alone showed an ORR of 18.2%, adding dB boosted this rate to 30.2%. Furthermore, patients in the experimental arm saw an average time without cancer progression of 11 months, and an overall survival time of nearly 26 months. This is a notable improvement compared to the standard treatment, which offered around 4 months of progression-free survival and 17 months overall survival.
Professor Juliet Gray from the University of Southampton and University Hospital Southampton, the study's corresponding author, expressed optimism: "These are really encouraging results, which will contribute towards developing better treatments for children with neuroblastoma." Building on these promising outcomes, the BEACON-2 trial is currently underway, exploring the potential of combining dinutuximab beta with chemotherapy, a treatment approach known as chemo-immunotherapy. This trial is now open in many UK centers, aiming to further refine chemo-immunotherapy for the benefit of more children.
Professor Amos Burke, Director of the Cancer Research UK Clinical Trials Unit at the University of Birmingham, emphasized the importance of these findings: "Neuroblastoma that comes back or doesn't respond to first-line treatment currently presents poor outcomes for the children who sadly have this disease. These results are very important and could improve the odds and lived experience for these children." The University of Birmingham remains committed to developing and trialing innovative treatments for children in need.
But here's where it gets controversial...
Neuroblastoma primarily affects children under the age of 5 years. In the UK alone, approximately 100 children between 0 and 14 years are diagnosed annually, according to Cancer Research UK, which co-funded the study along with Imagine for Margo, Solving Kids' Cancer UK, and Zoe4life, operating under the Innovative Therapies for Children with Cancer (ITCC) collaborative research group.
This cancer originates in immature nerve cells, usually within the abdomen of young children, forming small tumors. These tumors can sometimes be felt as a lump. Sadly, in about half of the cases, neuroblastoma spreads to other parts of the body, including the bones, skin, and liver.
The BEACON trial enrolled 65 patients, with an average age of 4 years. The patient group included 28 children with refractory neuroblastoma (not responding to initial treatment) and 37 with relapsing neuroblastoma (cancer returning after treatment).
In addition to assessing response rates and survival times, the BEACON consortium also evaluated the neurotoxicity of the treatments. Patients in the dB arm experienced lower-grade symptoms, such as drowsiness, in around a third of cases, compared to 9% in the standard treatment arm. Severe grade 3 symptoms were observed at low levels in the dB arm (2.3%) and were comparable to the standard treatment (4.5%).
And this is the part most people miss...
Previously reported findings from the BEACON consortium demonstrated that adding the anti-tumor drug bevacizumab to chemotherapy could shrink tumors. These results have already influenced how UK pediatric oncologists treat neuroblastoma. The ongoing BEACON-2 trial is further investigating combinations of drugs, including bevacizumab and dB chemoimmunotherapy.
What are your thoughts? Do you think these advancements in treatment offer a significant step forward in the fight against neuroblastoma? Are you optimistic about the future of chemo-immunotherapy for children? Share your opinions in the comments below!
